Literature DB >> 32187957

P2X7 receptor acts as an efficient drug target in regulating bone metabolism system.

Yutong Dong1, Yueqi Chen2, Lincheng Zhang1, Zhansong Tian3, Shiwu Dong4.   

Abstract

Skeletal system is a highly dynamic system going through continuous resorption and reconstruction to maintain homeostasis, which is influenced by numerous factors. Once the balance is disrupted, various kinds of bone diseases may occur such as osteoporosis. It has been well known that ATP (adenosine triphosphate), an important signaling molecule, is important in maintaining the dynamic balance of bone matrix. ATP mainly functions through P2X receptors, a kind of ATP receptors expressed by various kinds of bone cells to regulate the whole network of skeleton system. Among P2X receptors, P2X7 plays a crucial role in bone since P2X7 is widely expressed by bone cells and the mutation of P2X7 receptor is associated with kinds of bone diseases. It's acknowledged that P2X7 acts as a potential therapeutic target for clinical treatment of bone-related diseases but further investigations are needed for the practical application. However, since P2X7 has a complicated effect in many aspects, the exact role of P2X7 in skeleton system is ambiguous. This review discusses the function of P2X7 in bone and other cells and their general effect on skeleton system, especially focusing on the possible clinical application for bone diseases.
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  ATP; Bone metabolism diseases; Osteoblasts; Osteoclasts; P2X7 receptor

Mesh:

Substances:

Year:  2020        PMID: 32187957     DOI: 10.1016/j.biopha.2020.110010

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  The regulation of RANKL by mechanical force.

Authors:  Fumiyuki Sasaki; Mikihito Hayashi; Takehito Ono; Tomoki Nakashima
Journal:  J Bone Miner Metab       Date:  2020-09-05       Impact factor: 2.626

Review 2.  P2X7Rs: new therapeutic targets for osteoporosis.

Authors:  Haoyun Huang; Yu-Mei He; Miao-Miao Lin; Yanchao Wang; Xiaomei Zhang; Li Liang; Xueling He
Journal:  Purinergic Signal       Date:  2022-02-02       Impact factor: 3.765

3.  A selected small molecule prevents inflammatory osteolysis through restraining osteoclastogenesis by modulating PTEN activity.

Authors:  Yueqi Chen; Wenhui Hu; Yiran Wang; Yuheng Li; Xiaoming Li; Haibo Li; Yong Tang; Lincheng Zhang; Yutong Dong; Xiaochao Yang; Ye Wei; Shiwu Dong
Journal:  Clin Transl Med       Date:  2020-12

4.  Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.

Authors:  Yonggang Ma; Xueni Shi; Hongyan Zhao; Ruilong Song; Hui Zou; Jiaqiao Zhu; Zongping Liu
Journal:  Int J Mol Med       Date:  2022-03-10       Impact factor: 4.101

Review 5.  Multi-functional osteoclasts in matrix-based tissue engineering bone.

Authors:  Yue-Qi Chen; Wen-Hui Hu; Zi-Cai Dong; Shi-Wu Dong
Journal:  Chin J Traumatol       Date:  2021-11-26

Review 6.  Multitasking by the OC Lineage during Bone Infection: Bone Resorption, Immune Modulation, and Microbial Niche.

Authors:  Philip M Roper; Christine Shao; Deborah J Veis
Journal:  Cells       Date:  2020-09-24       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.